Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Expenses (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Operating Expenses for 5 consecutive years, with $182.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 28.57% year-over-year to $182.4 million, compared with a TTM value of $600.3 million through Dec 2025, up 28.04%, and an annual FY2025 reading of $600.3 million, up 28.04% over the prior year.
  • Operating Expenses was $182.4 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $156.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $182.4 million in Q4 2025 and bottomed at $42.8 million in Q3 2021.
  • Average Operating Expenses over 5 years is $88.5 million, with a median of $76.3 million recorded in 2023.
  • The sharpest move saw Operating Expenses decreased 3.98% in 2022, then surged 70.24% in 2024.
  • Year by year, Operating Expenses stood at $54.9 million in 2021, then increased by 1.75% to $55.8 million in 2022, then soared by 49.21% to $83.3 million in 2023, then skyrocketed by 70.24% to $141.8 million in 2024, then increased by 28.57% to $182.4 million in 2025.
  • Business Quant data shows Operating Expenses for KNSA at $182.4 million in Q4 2025, $156.8 million in Q3 2025, and $136.6 million in Q2 2025.